TY - JOUR
T1 - GlycA for long-term outcome in T2DM secondary prevention
AU - Zierfuss, Bernhard
AU - Höbaus, Clemens
AU - Herz, Carsten T.
AU - Pesau, Gerfried
AU - Mrak, Daniel
AU - Koppensteiner, Renate
AU - Schernthaner, Gerit-Holger
N1 - Publisher Copyright:
© 2020 The Authors
PY - 2021/1
Y1 - 2021/1
N2 - AIMS: Glycosylated acetyls (GlycA), a systemic marker of inflammation, were associated both with incident type 2 diabetes mellitus (T2DM) and incident cardiovascular (CV) disease. This study evaluates the predictive value of GlycA for long-term survival in patients with T2DM and peripheral artery disease (PAD).METHODS: GlycA (mmol/l) levels were measured by nuclear magnetic resonance spectroscopy in a cross-sectional cohort of patients with PAD (n = 319). Both all-cause and CV mortality were evaluated after a follow-up of 9.0 (IQR 6.5-9.5) years. During the follow-up 117 patients died, of those 64 events were of CV origin (PAD-T2DM subgroup: all-cause mortality n = 60, CV-mortality n = 32).RESULTS: PAD-T2DM showed a tendency towards a worse CV risk factor profile and a higher percentage of known coronary artery disease (24.9% vs 43.5%, p < 0.001). GlycA levels were higher in PAD-T2DM (1.6 ± 0.2 vs. 1.53 ± 0.18, p = 0.002). GlycA predicted all-cause mortality after multivariable adjustment for traditional CV risk factors (HR for 1 SD increase 1.51, 95% confidence interval 1.03-2.19) in PAD-T2DM, while no association could be seen with CV-mortality (1.22, 0.73-2.06).CONCLUSIONS: GlycA was capable of predicting long-term outcome in PAD patients with T2DM. Thus, GlycA might reflect the added inflammatory burden of T2DM in systemic atherosclerosis.
AB - AIMS: Glycosylated acetyls (GlycA), a systemic marker of inflammation, were associated both with incident type 2 diabetes mellitus (T2DM) and incident cardiovascular (CV) disease. This study evaluates the predictive value of GlycA for long-term survival in patients with T2DM and peripheral artery disease (PAD).METHODS: GlycA (mmol/l) levels were measured by nuclear magnetic resonance spectroscopy in a cross-sectional cohort of patients with PAD (n = 319). Both all-cause and CV mortality were evaluated after a follow-up of 9.0 (IQR 6.5-9.5) years. During the follow-up 117 patients died, of those 64 events were of CV origin (PAD-T2DM subgroup: all-cause mortality n = 60, CV-mortality n = 32).RESULTS: PAD-T2DM showed a tendency towards a worse CV risk factor profile and a higher percentage of known coronary artery disease (24.9% vs 43.5%, p < 0.001). GlycA levels were higher in PAD-T2DM (1.6 ± 0.2 vs. 1.53 ± 0.18, p = 0.002). GlycA predicted all-cause mortality after multivariable adjustment for traditional CV risk factors (HR for 1 SD increase 1.51, 95% confidence interval 1.03-2.19) in PAD-T2DM, while no association could be seen with CV-mortality (1.22, 0.73-2.06).CONCLUSIONS: GlycA was capable of predicting long-term outcome in PAD patients with T2DM. Thus, GlycA might reflect the added inflammatory burden of T2DM in systemic atherosclerosis.
KW - Cohort study
KW - Macrovascular disease
KW - Mortality
KW - Peripheral artery disease
KW - Type 2 diabetes
KW - Cross-Sectional Studies
KW - Humans
KW - Middle Aged
KW - Male
KW - Glycosylation
KW - Magnetic Resonance Spectroscopy/methods
KW - Peripheral Arterial Disease/diagnosis
KW - Secondary Prevention/methods
KW - Diabetes Mellitus, Type 2/mortality
KW - Survival Analysis
KW - Aged, 80 and over
KW - Adult
KW - Biomarkers/blood
KW - Female
KW - Aged
UR - http://www.scopus.com/inward/record.url?scp=85098049338&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2020.108583
DO - 10.1016/j.diabres.2020.108583
M3 - Journal article
C2 - 33307129
SN - 1872-8227
VL - 171
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
M1 - 108583
ER -